You need to enable JavaScript to run this app.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
AML Types
Signaling pathway mutations
Epigenetic modifier mutations
Origin
Chromosomal aberrations
Nucleophosmin mutations
Tumor suppressor mutations
Spliceosome mutations
Transcription factor mutations
Cohesin mutations
View all Types
Jeffrey Lancet
Executive Steering Committee Member
Jeffrey Lancet
Executive Steering Committee Member
Types
ASXL1
Core binding factor
De novo
DNMT3A
EZH2
FLT3-ITD
IDH1
IDH2
KRAS
Myelodysplasia-related
NF1
NPM1
NRAS
PTPN11
RUNX1
Secondary
SF3B1
SRSF2
STAG2
TET2
Therapy-related
TP53
U2AF1
ZRSR2
Interventions
Allo-HSCT
Azacitidine
CC-486
CPX-351
Cusatuzumab
Cytarabine
Decitabine
Enasidenib
Gilteritinib
Ivosidenib
Midostaurin
Sorafenib
Venetoclax
Events
ASCO 2017
ASCO 2018
ASCO 2020
ASH 2017
ASH 2019
ASH 2020
ISAL 2019
SOHO 2019
Trials
NCT01696084
RATIFY
SORAML
VIALE-A
VIALE-C
All
|
3 Articles
|
8 Videos
|
0 Podcasts